Pro: "Antidote for new anticoagulants" - Specific target of inhibition requires a specific target for neutralisation

Thrombosis and Haemostasis

Volumn 108, Issue 4, 2012, Pages 621-622

  Roldán, Vanessa ^a   Marín, Francisco ^b  

^a HOSPITAL MORALES MESEGUER   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; DABIGATRAN; FRESH FROZEN PLASMA; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIVAROXABAN; VITAMIN K GROUP; WARFARIN;

ANTICOAGULATION; ARTERY THROMBOSIS; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; DRUG EFFICACY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTHROMBIN TIME; RISK;

ANIMALS; ANTICOAGULANTS; ANTIDOTES; BLOOD COAGULATION FACTORS; HALF-LIFE; HEMORRHAGE; HEMOSTASIS; HUMANS; RENAL DIALYSIS; VITAMIN K;

EID: 84867260031     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-06-0440     Document Type: Article

References (22)

1. Ageno W, Gallus AS, Wittkowsky A, et al.; American College of Chest Physicians. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e44S-88S.
2. Keeling D, Baglin T, Tait C, et al.; British Committee for Standards in Haematology. Guidelines on oral anticoagulation with warfarin - fourth edition. Br J Haematol 2011; 154: 311-324.
3. Rosovsky RP, Crowther MA. What is the evidence for the off-label use of recombinant factor VIIa (rFVIIa) in the acute reversal of warfarin? ASH evidence-based review 2008. Hematology Am Soc Hematol Educ Program 2008; 36-38.
4. Levi M, Levy JH, Andersen HF, et al. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010; 363: 1791-1800.
5. Dentali F, Marchesi C, Pierfranceschi MGet al. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost 2011; 106: 429-438.
6. Weitz JI. Factor Xa and thrombin as targets for new oral anticoagulants. Thromb Res 2011; 127 (Suppl 2): S5-S12.
7. Phillips K, Ansell J. The clinical implications of new oral anticoagulants: Will the potential advantages be achieved? Thromb Haemost 2010; 103: 34-39.
8. Miesbach W, Seifried E. New direct oral anticoagulants current therapeutic options and treatment recommendations for bleeding complications. Thromb Haemost 2012; 108: 625-632.
9. Levi M, Eerenberg E, Kamphuisen PW. Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. J Thromb Haemost 2011; 9: 1705-1712.
10. Fukuda T, Honda Y, Kamisato C, et al. Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents. Thromb Haemost 2012; 107: 253-259.
11. Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of Rivaroxaban and Dabigatran by prothrombin complex concentrate: A randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573-1579.
12. Marlu R, Hodaj E, Paris A, et al. Effect of non-specific reversal agents on anticoagulant activity of Dabigatran and Rivaroxaban. A randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012; 108: 217-224.
13. van Ryn J, Schurer J, Kink-Eiband M, et al. The successful reversal of Dabigatran induced bleeding by coagulation factor concentrates in a rat tail bleeding model do not correlate with ex vivo markers of anticoagulation. Blood (ASH Annual Meeting Abstracts) 2011; 118: 2316.
14. Schulman S, Crowther MA. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood 2012; 119: 3016-3023.
15. Holbrook A, Schulman S, Witt DM, et al.; American College of Chest Physicians. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e152S-84S.
16. Kaatz S, Kouides PA, Garcia DA, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 2012; 87 (Suppl 1): S141-145.
17. Rodgers GM. Prothrombin complex concentrates in emergency bleeding disorders. Am J Hematol 2012; epub ahead of print.
18. Gilmore R, Harmon S, Keane G, et al. Variation in anticoagulant composition regulates differential effects of prothrombin complex concentrates on thrombin generation. J Thromb Haemost 2009; 7: 2154-2156.
19. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-1127.
20. Pengo V, Crippa L, Falanga A, et al.; Italian Federation of Thrombosis Centers. Questions and answers on the use of Dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost 2011; 106: 868-876.
21. Marín F, Roldán V, Lip GY. Dabigatran for the prevention of stroke in atrial fibrillation: is RE-LY reliable? Expert Opin Pharmacother 2012; 13: 1087-1090.
22. Bauer KA. Reversal of antithrombotic agents. Am J Hematol 2012; 87 (Suppl 1): S119-126.